Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
3.310
-0.080 (-2.36%)
At close: Oct 6, 2026, 4:00 PM EDT
3.320
+0.010 (0.30%)
After-hours: Oct 6, 2026, 7:11 PM EDT
Ardelyx Revenue
Ardelyx had revenue of $120.88M in the quarter ending June 30, 2026, with 23.77% growth. This brings the company's revenue in the last twelve months to $450.89M, up 16.77% year-over-year. In the year 2025, Ardelyx had annual revenue of $407.32M with 22.09% growth.
Revenue (ttm)
$450.89M
Revenue Growth
+16.77%
P/S Ratio
1.81
Revenue / Employee
$922,074
Employees
489
Market Cap
824.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 407.32M | 73.71M | 22.09% |
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 276.79M |
| Ginkgo Bioworks Holdings | 132.42M |
| Monte Rosa Therapeutics | 28.73M |
| SL Science Holding | 3.27M |
| Attovia Therapeutics | 1.80M |
ARDX News
- 1 day ago - Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 - GlobeNewsWire
- 4 days ago - Kaplan Fox Reminds Ardelyx, Inc. (ARDX) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 16, 2026 - Newsfile Corp
- 5 days ago - Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX) - Newsfile Corp
- 6 days ago - Robbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company's Commercial Performance and Growth Prospects for its Two Core Drug Products - Newsfile Corp
- 6 days ago - Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards - GlobeNewsWire
- 12 days ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX - PRNewsWire
- 20 days ago - Ardelyx Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 21 days ago - Ardelyx management to meet with Piper Sandler - TheFly